POZEN Announces PA32540 Provides Superior Antiplatlet Effects over a Standard of Care Regimen ...
15:37 EDT 29 Aug 2012 | LaMerie
POZEN Presents Phase 1 Data at European Society of Cardiologists 2012 Congress
Original Article: POZEN Announces PA32540 Provides Superior Antiplatlet Effects over a Standard of Care Regimen ...
More From BioPortfolio on "POZEN Announces PA32540 Provides Superior Antiplatlet Effects over a Standard of Care Regimen ..."
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
